M

Myomo Inc
AMEX:MYO

Watchlist Manager
Myomo Inc
AMEX:MYO
Watchlist
Price: 1.08 USD 9.09%
Market Cap: 41.5m USD

Myomo Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Myomo Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
M
Myomo Inc
AMEX:MYO
Stock-Based Compensation
$1.6m
CAGR 3-Years
10%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Stock-Based Compensation
$53m
CAGR 3-Years
-39%
CAGR 5-Years
-26%
CAGR 10-Years
-11%
Boston Scientific Corp
NYSE:BSX
Stock-Based Compensation
$297m
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
11%
Stryker Corp
NYSE:SYK
Stock-Based Compensation
$240m
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
11%
Abbott Laboratories
NYSE:ABT
Stock-Based Compensation
$662m
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
9%
Intuitive Surgical Inc
NASDAQ:ISRG
Stock-Based Compensation
$761.9m
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
16%
No Stocks Found

Myomo Inc
Glance View

Market Cap
40.8m USD
Industry
Health Care

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.

MYO Intrinsic Value
1.61 USD
Undervaluation 33%
Intrinsic Value
Price
M

See Also

What is Myomo Inc's Stock-Based Compensation?
Stock-Based Compensation
1.6m USD

Based on the financial report for Jun 30, 2025, Myomo Inc's Stock-Based Compensation amounts to 1.6m USD.

What is Myomo Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
24%

Over the last year, the Stock-Based Compensation growth was 75%. The average annual Stock-Based Compensation growth rates for Myomo Inc have been 10% over the past three years , 24% over the past five years .

Back to Top